UNITED THERAPEUTICS CORP (UTHR) Stock Price, Quote, News and Overview
NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD
UTHR Quote, Performance and Key Statistics
285.97
-3.97 (-1.37%)
The current stock price of UTHR is 285.97 USD. In the past month the price decreased by -9.17%. In the past year, price decreased by -10.23%.
UTHR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.05 | 327.47B | ||
| AMGN | AMGEN INC | 13.5 | 150.75B | ||
| GILD | GILEAD SCIENCES INC | 13.69 | 131.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.49B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.74 | 56.18B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.98B | ||
| ARGX | ARGENX SE - ADR | 97.48 | 34.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.83 | 28.90B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.42B | ||
| INSM | INSMED INC | N/A | 19.10B | ||
| BIIB | BIOGEN INC | 8.05 | 18.65B |
Related stock screener links
About UTHR
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,305 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Company Info
UNITED THERAPEUTICS CORP
1000 Spring St
Silver Spring MARYLAND 20910 US
CEO: Martine A. Rothblatt
Employees: 1305
Phone: 13016089292
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the stock price of UNITED THERAPEUTICS CORP today?
The current stock price of UTHR is 285.97 USD. The price decreased by -1.37% in the last trading session.
What is the ticker symbol for UNITED THERAPEUTICS CORP stock?
The exchange symbol of UNITED THERAPEUTICS CORP is UTHR and it is listed on the Nasdaq exchange.
On which exchange is UTHR stock listed?
UTHR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for UNITED THERAPEUTICS CORP stock?
20 analysts have analysed UTHR and the average price target is 392.46 USD. This implies a price increase of 37.24% is expected in the next year compared to the current price of 285.97. Check the UNITED THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UNITED THERAPEUTICS CORP worth?
UNITED THERAPEUTICS CORP (UTHR) has a market capitalization of 12.90B USD. This makes UTHR a Large Cap stock.
How many employees does UNITED THERAPEUTICS CORP have?
UNITED THERAPEUTICS CORP (UTHR) currently has 1305 employees.
What are the support and resistance levels for UNITED THERAPEUTICS CORP (UTHR) stock?
UNITED THERAPEUTICS CORP (UTHR) has a support level at 281.15 and a resistance level at 300.61. Check the full technical report for a detailed analysis of UTHR support and resistance levels.
Is UNITED THERAPEUTICS CORP (UTHR) expected to grow?
The Revenue of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 12.18% in the next year. Check the estimates tab for more information on the UTHR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy UNITED THERAPEUTICS CORP (UTHR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of UTHR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of UTHR, evaluating the profitability, health, valuation and growth aspects
- UNITED THERAPEUTICS CORP (UTHR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UNITED THERAPEUTICS CORP (UTHR) Sales and EPS estimates to see what analysts future expectations are.
- UNITED THERAPEUTICS CORP (UTHR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UNITED THERAPEUTICS CORP (UTHR) Insider and Institutional Ownership to learn about the owners and their transactions.
- UNITED THERAPEUTICS CORP (UTHR) Stock Chart to make your own analysis
- UNITED THERAPEUTICS CORP (UTHR) Latest news and press-releases to stay up to date.
Does UNITED THERAPEUTICS CORP (UTHR) stock pay dividends?
UTHR does not pay a dividend.
When does UNITED THERAPEUTICS CORP (UTHR) report earnings?
UNITED THERAPEUTICS CORP (UTHR) will report earnings on 2025-07-29, after the market close.
What is the Price/Earnings (PE) ratio of UNITED THERAPEUTICS CORP (UTHR)?
The PE ratio for UNITED THERAPEUTICS CORP (UTHR) is 11.41. This is based on the reported non-GAAP earnings per share of 25.06 and the current share price of 285.97 USD. Check the full fundamental report for a full analysis of the valuation metrics for UTHR.
What is the Short Interest ratio of UNITED THERAPEUTICS CORP (UTHR) stock?
The outstanding short interest for UNITED THERAPEUTICS CORP (UTHR) is 4.24% of its float. Check the ownership tab for more information on the UTHR short interest.
UTHR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to UTHR. When comparing the yearly performance of all stocks, UTHR is a bad performer in the overall market: 77.78% of all stocks are doing better.
UTHR Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to UTHR. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties.
UTHR Financial Highlights
Over the last trailing twelve months UTHR reported a non-GAAP Earnings per Share(EPS) of 25.06. The EPS increased by 18.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 40.44% | ||
| ROA | 15.63% | ||
| ROE | 17.79% | ||
| Debt/Equity | 0 |
UTHR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to UTHR. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 14.83% and a revenue growth 12.18% for UTHR